Temps de lecture : 3 min
Since 1991, when the first LASIK procedure was preformed in the United States, approximately 800,000 people have had this elective procedure done on one or moth of their eyes. The numbers of surgeries have more than doubled every year since 1997. Despite these numbers, approximately 45 percent of what are called refractive errors – eyesight problems corrected with glasses or contacts could not be corrected by laser – until now.
Joseph Dello Russo, Director of the Dello Russo Laser Vision in Manhattan, is the first in the Northeast to introduce and popularize LADARVision. Dr Joseph Dello Russo, considered a pioneer in the field of laser vision correction, having performed more than 18,000 laser procedure since 1990, was one of the 19 FDA investigators during the clinical trial.
According to Dr Dello Russo, “With the LADARVision system approval, we can now treat near-sightedness, farsightedness, astigmatism, farsightedness with astigmatism, or any combination of the above which they call mixed astigmatism. Everyone is now a candidate for laser correction as long as their eyes are healthy.
The “Flying Spot” LADARVision system has several advantages over the first generations lasers. First, LADARVision is the only approved and commercially available laser that uses a radar eye tracking and small-spot 1mm scanning technology. This is especially significant because during and laser vision correction procedure, the eye moves in tiny ways. These involuntary movements are completely nautral.
They are also impossible to predict or prevent.
The “Flying Spot” laser adapts Star Wars technology from NASA’s Strategic Defense Initiative era to develop the tracker in order to address the problem of involuntary eye movement. In simple terms, the Flying Spot laser has the ability to actively track the tiniest eye movement and within seconds retarget the beam to the correct spot on the cornea. Hence, “Flying Spot.”
Secondly, the ‘cold’ laser beam is delivered in a very fine spot that literally flies over the cornea and gently reshapes it. The amount of corneal tissue that is removed is less that the width of a single human hair.
The result is a very smooth treatment area that gives superior visual results and assists in rapid healing.
Finally, LADARVision patients typically do not complain of night glare and halos that one hears from patients treated with first-generation lasers. Because LADARVision treats a larger area of the cornea, it virtually eliminates the possibility of developing such problems following treatment.
LADARVision is a product of Alcon, Inc., Fort Worth, Texas, a global leader in the research, development, manufacturing, and marketing of ophthalmic products.
Source : communiqué de presse
Vous avez la parole !
pour pouvoir poster des commentaires
Nos lecteurs ont aussi lu...
Une nouvelle application permet aux personnes aveugles ou malvoyantes d'identifier les médicaments
Publié le 23 octobre 2026
Quelques semaines après la Conférence nationale du handicap, l'association HandiCaPZéro lance l'application « HdCZ Santé ». Cette solution vise à renforcer l'autonomie…
De la théorie à la restauration de la vue : l’optogénétique couronnée du prix Nobel de Médecine 2026
Publié le 16 octobre 2026
Le prix Nobel de physiologie ou médecine 2026 a été décerné aux pionniers de l’optogénétique, Karl Deisseroth, Peter Hegemann et Georg Nagel. Cette prestigieuse…
DMLA sèche : vers un premier traitement par voie orale
Publié le 15 octobre 2026
La DMLA sèche touche de nombreux patients pour lesquels les options thérapeutiques demeurent limitées, particulièrement aux stades initiaux de la maladie.
Les dernières news
Complémentaires santé : le Conseil constitutionnel invalide l'interdiction d'augmenter les tarifs en 2026
Publié le 23 octobre 2026
Le Conseil constitutionnel a annoncé, ce 23 octobre, l'annulation de la mesure issue de la loi de financement de la Sécurité sociale (LFSS) pour 2026 qui interdisait aux…
Sondage : comment qualifiez-vous l'activité de votre magasin d'optique cette semaine du 19 octobre ?
Publié le 23 octobre 2026
Vitrines calfeutrées, fermetures anticipées par précaution, retombée nette du flux piéton dans les centres-villes métropolitains... Après le week-end particulièrement…
Une nouvelle application permet aux personnes aveugles ou malvoyantes d'identifier les médicaments
Publié le 23 octobre 2026
Quelques semaines après la Conférence nationale du handicap, l'association HandiCaPZéro lance l'application « HdCZ Santé ». Cette solution vise à renforcer l'autonomie…